Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes

ClinicalTrials.gov ID: NCT04982575

Public ClinicalTrials.gov record NCT04982575. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 9:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy and Safety of Co-administration of Cagrilintide s.c. 2.4 mg and Semaglutide s.c. 2.4 mg Once Weekly in Subjects With Type 2 Diabetes

Study identification

NCT ID
NCT04982575
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
92 participants

Conditions and interventions

Interventions

  • Cagrilintide 2.4 mg Drug
  • Placebo (cagrilintide) Drug
  • Placebo (semaglutide) Drug
  • Semaglutide 2.4 mg Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 1, 2021
Primary completion
Jul 6, 2022
Completion
Jul 6, 2022
Last update posted
Dec 22, 2025

2021 – 2022

United States locations

U.S. sites
23
U.S. states
14
U.S. cities
22
Facility City State ZIP Site status
Uni of Alabama at Birmingham Birmingham Alabama 35233
Valley Research Fresno California 93720
Pacific Clinical Studies Los Alamitos California 90720
Velocity Clin Res Los Angeles Los Angeles California 90017
Encompass Clinical Research_Spring Valley Spring Valley California 91978
New West Physicians,Inc. Golden Colorado 80401
FPA Clinical Research Kissimmee Florida 34741
Florida Inst For Clin Res Orlando Florida 32825
Clinical Trial Res Assoc,Inc Plantation Florida 33324
Ellipsis Group Alpharetta Georgia 30022
East West Med Res Inst Honolulu Hawaii 96814
Macoupin Research Group Gillespie Illinois 62033
MD Medical Research Oxon Hill Maryland 20745
PharmQuest Life Sciences LLC Greensboro North Carolina 27408
Accellacare Wilmington North Carolina 28401
Lillestol Research LLC Fargo North Dakota 58104
Plains Clinical Research Center, LLC_Fargo Fargo North Dakota 58104
Holston Medical Group Kingsport Tennessee 37660
Velocity Clinical Res-Dallas Dallas Texas 75230
PlanIt Research, PLLC Houston Texas 77079
DCOL Ctr for Clin Res Longview Texas 75605
Selma Medical Associates Winchester Virginia 22601-3834
Capital Clin Res Ctr,LLC Olympia Washington 98502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04982575, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 22, 2025 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04982575 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →